Supplementary Table 1: Inferential analysis HFMSE and RULM

	HFMSE					RULM				
	Value	SE	DF	t-value	p-value	Value	SE	DF	t-value	p-value
Baseline_m14 vs m14_m26	**0.89**	**0.29**	**1060**	**3.10**	**0.002**	0.07	0.15	976	0.49	0.63
Baseline_m14 vs m26_m38	-0.14	0.44	1060	-0.32	0.75	0.06	0.23	976	0.26	0.8
Age at symptom onset	0.002	0.003	180	0.58	0.56	0.003	0.001	169	2.28	0.02
Baseline score	**-0.07**	**0.02**	**180**	**-2.95**	**0.004**	**-0.16**	**0.02**	**169**	**-7.71**	**0.000**
SMN2 copy number	-0.20	0.51	180	-0.40	0.69	-0.48	0.22	169	-2.21	0.03
Age at start of treatment	-0.002	0.002	180	-1.19	0.24	-0.001	0.001	169	-1.40	0.16
Gender (m)	-0.19	0.49	180	-0.40	0.69	-0.21	0.21	169	-1.01	0.32

Inferential analysis evaluates the effect of age at diagnosis, age at start of treatment, *SMN2* copy number (≤3 *SMN2* copies vs. ≥4 *SMN2* copies), gender, baseline score, and past time from baseline on changes in HFMSE or RULM.

*Standard error = SE; degree of freedom = DF

Supplementary Table 2: Fatigability in 6MWT

		First 50 m	Last 50 m
Pediatric walkers (n=37)	Baseline	48.9 [39.6; 59.4]	51.8 [39.6; 64.1]
	Last visit	46.3 [37.1; 55.5]	53.1 [41.9; 64.3]
Adult walkers (n=56)	Baseline	44.3 [38.7; 49.9]	51.2 [43.3; 59.2]
	Last visit	42.5 [36.2; 48.9]	49.2 [38.4; 60.0]

Data are listed in seconds as mean and 99% confidence interval.